Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Vain PDF

25 päivää sitten

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
210--
608--
1 000--
2 100--
31--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 25 min sitten
    ·
    25 min sitten
    ·
    have a small lump of money. around 20 k have some some nice stocks I can put them in so that they get a good of nice start boost. yes I eat and choose sell but never wrong with input
  • 2 t sitten
    ·
    2 t sitten
    ·
    For those who haven't seen investornytt's talk with Erik 10. April. https://www.youtube.com/live/92FiyAAduJw?si=UGQ5Cr-t5K3WMEF5&t=1390
  • 5 t sitten
    ·
    5 t sitten
    ·
    Following the latest mentions of Hantavirus, including its discovery in a closed environment such as a cruise ship, interest in new RNA platforms has once again begun to rise among both researchers and investors. This is not because the disease has suddenly become global, but because it reminds the market how quickly a rare virus can create a need for a vaccine and preparedness solution that can be developed extremely quickly. In this context, clear movements have been observed in the stock market, where Moderna experienced an upswing in connection with increased mention of their RNA platform and possible application in new infectious diseases, including hantavirus-related research. At the same time, Traws Pharma rose significantly following speculative interest in antiviral programs targeting rare zoonotic viruses, with hantavirus being mentioned as an example in the investment community. If one considers Circio's circVec platform with significantly higher and more sustained protein expression at a lower dose and simultaneously a better safety profile, it will have direct relevance in scenarios such as hantavirus preparedness. Not because the disease is global, but because it requires a platform that can react quickly and protect at-risk groups (frail, elderly, and already ill people) effectively without complex vaccination programs. This is precisely where Circio potentially positions itself differently from traditional mRNA players: not as a competitor for rapid vaccine production, but as a possible "extension technology" that can make immunity more durable and effective. Look back at Moderna and Pfizer's astronomical gains during the last pandemic. Now imagine a licensing agreement with royalties for Circio when using the platform in their vaccines. I see ONLY gigantic potential for Circio in the future. 💰
    2 t sitten
    ·
    2 t sitten
    ·
    Just hold/increase the portfolio here. So many triggers and opportunities ahead…
  • 9 t sitten
    ·
    9 t sitten
    ·
    It is said that those who have made money on stock investments live by: Not restless and short-term but Calm and long-term. such as the largest shareholder in Circicio - Høse AS
    2 t sitten
    ·
    2 t sitten
    ·
    It is also said that those who have made money on stock investments have not done so via preclinical biotech 😂
  • 12 t sitten
    ·
    12 t sitten
    ·
    I just want to hear from the experienced ones. I myself have shares in circio. What happens after an acquisition? Will the acquiring company take circio over into theirs and we get shares there in their company. Or will circio continue as its own entity. With a higher share price. It is a serious question. As I am considering selling thereafter (before human trials)
    9 t sitten
    ·
    9 t sitten
    ·
    Yes, but an important point is that with so many touchpoints, it won't just be one, but several who buy into the use of circio's product/s.
    7 t sitten
    ·
    7 t sitten
    ·
    Touchpoints? The acquirer pays out the shares to the owners and you get money in your account. That has nothing to do with touchpoints.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

25 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 25 min sitten
    ·
    25 min sitten
    ·
    have a small lump of money. around 20 k have some some nice stocks I can put them in so that they get a good of nice start boost. yes I eat and choose sell but never wrong with input
  • 2 t sitten
    ·
    2 t sitten
    ·
    For those who haven't seen investornytt's talk with Erik 10. April. https://www.youtube.com/live/92FiyAAduJw?si=UGQ5Cr-t5K3WMEF5&t=1390
  • 5 t sitten
    ·
    5 t sitten
    ·
    Following the latest mentions of Hantavirus, including its discovery in a closed environment such as a cruise ship, interest in new RNA platforms has once again begun to rise among both researchers and investors. This is not because the disease has suddenly become global, but because it reminds the market how quickly a rare virus can create a need for a vaccine and preparedness solution that can be developed extremely quickly. In this context, clear movements have been observed in the stock market, where Moderna experienced an upswing in connection with increased mention of their RNA platform and possible application in new infectious diseases, including hantavirus-related research. At the same time, Traws Pharma rose significantly following speculative interest in antiviral programs targeting rare zoonotic viruses, with hantavirus being mentioned as an example in the investment community. If one considers Circio's circVec platform with significantly higher and more sustained protein expression at a lower dose and simultaneously a better safety profile, it will have direct relevance in scenarios such as hantavirus preparedness. Not because the disease is global, but because it requires a platform that can react quickly and protect at-risk groups (frail, elderly, and already ill people) effectively without complex vaccination programs. This is precisely where Circio potentially positions itself differently from traditional mRNA players: not as a competitor for rapid vaccine production, but as a possible "extension technology" that can make immunity more durable and effective. Look back at Moderna and Pfizer's astronomical gains during the last pandemic. Now imagine a licensing agreement with royalties for Circio when using the platform in their vaccines. I see ONLY gigantic potential for Circio in the future. 💰
    2 t sitten
    ·
    2 t sitten
    ·
    Just hold/increase the portfolio here. So many triggers and opportunities ahead…
  • 9 t sitten
    ·
    9 t sitten
    ·
    It is said that those who have made money on stock investments live by: Not restless and short-term but Calm and long-term. such as the largest shareholder in Circicio - Høse AS
    2 t sitten
    ·
    2 t sitten
    ·
    It is also said that those who have made money on stock investments have not done so via preclinical biotech 😂
  • 12 t sitten
    ·
    12 t sitten
    ·
    I just want to hear from the experienced ones. I myself have shares in circio. What happens after an acquisition? Will the acquiring company take circio over into theirs and we get shares there in their company. Or will circio continue as its own entity. With a higher share price. It is a serious question. As I am considering selling thereafter (before human trials)
    9 t sitten
    ·
    9 t sitten
    ·
    Yes, but an important point is that with so many touchpoints, it won't just be one, but several who buy into the use of circio's product/s.
    7 t sitten
    ·
    7 t sitten
    ·
    Touchpoints? The acquirer pays out the shares to the owners and you get money in your account. That has nothing to do with touchpoints.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
210--
608--
1 000--
2 100--
31--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

25 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 25 min sitten
    ·
    25 min sitten
    ·
    have a small lump of money. around 20 k have some some nice stocks I can put them in so that they get a good of nice start boost. yes I eat and choose sell but never wrong with input
  • 2 t sitten
    ·
    2 t sitten
    ·
    For those who haven't seen investornytt's talk with Erik 10. April. https://www.youtube.com/live/92FiyAAduJw?si=UGQ5Cr-t5K3WMEF5&t=1390
  • 5 t sitten
    ·
    5 t sitten
    ·
    Following the latest mentions of Hantavirus, including its discovery in a closed environment such as a cruise ship, interest in new RNA platforms has once again begun to rise among both researchers and investors. This is not because the disease has suddenly become global, but because it reminds the market how quickly a rare virus can create a need for a vaccine and preparedness solution that can be developed extremely quickly. In this context, clear movements have been observed in the stock market, where Moderna experienced an upswing in connection with increased mention of their RNA platform and possible application in new infectious diseases, including hantavirus-related research. At the same time, Traws Pharma rose significantly following speculative interest in antiviral programs targeting rare zoonotic viruses, with hantavirus being mentioned as an example in the investment community. If one considers Circio's circVec platform with significantly higher and more sustained protein expression at a lower dose and simultaneously a better safety profile, it will have direct relevance in scenarios such as hantavirus preparedness. Not because the disease is global, but because it requires a platform that can react quickly and protect at-risk groups (frail, elderly, and already ill people) effectively without complex vaccination programs. This is precisely where Circio potentially positions itself differently from traditional mRNA players: not as a competitor for rapid vaccine production, but as a possible "extension technology" that can make immunity more durable and effective. Look back at Moderna and Pfizer's astronomical gains during the last pandemic. Now imagine a licensing agreement with royalties for Circio when using the platform in their vaccines. I see ONLY gigantic potential for Circio in the future. 💰
    2 t sitten
    ·
    2 t sitten
    ·
    Just hold/increase the portfolio here. So many triggers and opportunities ahead…
  • 9 t sitten
    ·
    9 t sitten
    ·
    It is said that those who have made money on stock investments live by: Not restless and short-term but Calm and long-term. such as the largest shareholder in Circicio - Høse AS
    2 t sitten
    ·
    2 t sitten
    ·
    It is also said that those who have made money on stock investments have not done so via preclinical biotech 😂
  • 12 t sitten
    ·
    12 t sitten
    ·
    I just want to hear from the experienced ones. I myself have shares in circio. What happens after an acquisition? Will the acquiring company take circio over into theirs and we get shares there in their company. Or will circio continue as its own entity. With a higher share price. It is a serious question. As I am considering selling thereafter (before human trials)
    9 t sitten
    ·
    9 t sitten
    ·
    Yes, but an important point is that with so many touchpoints, it won't just be one, but several who buy into the use of circio's product/s.
    7 t sitten
    ·
    7 t sitten
    ·
    Touchpoints? The acquirer pays out the shares to the owners and you get money in your account. That has nothing to do with touchpoints.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
210--
608--
1 000--
2 100--
31--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki